PARNF
vs
S&P 500
PARNF
S&P 500
Over the past 12 months, PARNF has underperformed S&P 500, delivering a return of 0% compared to the S&P 500's +21% growth.
Stocks Performance
PARNF vs S&P 500
Performance Gap
PARNF vs S&P 500
Performance By Year
PARNF vs S&P 500
Compare the stock's returns with its benchmark index and competitors. Gain insights into its relative performance over time.
Parnell Pharmaceuticals Holdings Ltd
Glance View
Parnell Pharmaceuticals Holdings Ltd. operates as a veterinary pharmaceutical company. The company is headquartered in Alexandria, New South Wales. The company went IPO on 2014-06-18. The firm is focused on developing, manufacturing and commercializing animal health solutions. The principal activities of the Company include manufacture for global sale of animal pharmaceutical product, and research and development of pharmaceutical products for global animal health markets. The firm operates through four segments: Companion Animal, Production Animal-U.S., Production Animal-Rest of World and Manufacturing Operations. The company augments its pharmaceutical products with its FETCH and mySYNCH software platforms. The company offers disease-modifying product, Zydax, for the treatment of osteoarthritis (OA). Its reproductive hormone products include estroPLAN and GONAbreed. The company has a nutraceutical product, Glyde. The company also markets a non-steroidal anti-inflammatory drug (NSAID), called Tergive. The company is developing a pipeline of clinical drug candidates, such as PAR 121, PAR 122, PAR 101, PAR 081 and PAR 061.
